Product Overview
Dragon Pharma Aicar 50mg is a single lyophilised vial of 50 mg of 5-aminoimidazole-4-carboxamide ribonucleotide, a compound better known as AICAR or by its international non-proprietary name, acadesine. The molecule is a nucleoside analogue whose target is AMP activated protein kinase, the switch that reports scarce energy inside a cell; turning it on forces the tissue toward oxidation rather than storage. That mechanism, not an anabolic one, is the reason the material sits in a research catalogue.
Its history is medical rather than athletic. Acadesine was developed from the 1980s as a protectant for heart muscle during ischaemia, carries the ATC code C01EB13, and was also examined in acute lymphoblastic leukaemia. A licence for the cardiac use went to Schering-Plough in 2007, and the phase III programme behind it was halted at the end of 2010 for futility, which is why no approved dose exists to borrow. The compound's second life is laboratory work on metabolism, where mouse experiments at the Salk Institute in 2008 showed better endurance and a shift of fast muscle fibres towards the slower, more oxidative type; the same paper reported that roughly 40 percent of the gene response to training could be reproduced in untrained mice when the compound was combined with GW501516.
Two practical points separate this vial from the peptides on the same shelf. Human oral availability is estimated below 5 percent, so the laboratory route is injection, and the compound is prohibited in sport under the metabolic modulator class, which makes it a controlled item at any tested competition. Neighbours in the same catalogue category include MOTS-c 10 mg and AOD 9604.
Research Dosing Reference
Everything below is arithmetic or an animal figure. No validated human amount exists for this material, and the source notes that the animal dosing was calculated per kilogram of body weight and does not transfer mechanically to a person.
| Solvent | Bacteriostatic water into the 50 mg cake; the vial is swirled, not shaken |
| Concentration at 5 ml | 50 mg in 5 ml gives 10 mg per ml, so 1 mg equals 0.1 ml, which is 10 units on a U-100 syringe |
| Concentration at 2 ml | 50 mg in 2 ml gives 25 mg per ml; 1 mg is 0.04 ml, and small volumes like this call for a low-dead-space syringe |
| Concentration at 10 ml | 50 mg in 10 ml gives 5 mg per ml, so 1 mg equals 0.2 ml or 20 units |
| Animal study amount | Rodent work scaled the amount to mass: 0.5 mg for every gram of body weight, injected subcutaneously once a day across 14 days; an animal figure, not a human dose |
| Vendor conventions | Practitioner write-ups quote 1-2 mg a day across a course; the sources label this as practice rather than data |
| Vial yield | 50 mg covers 50 days at 1 mg a day and 25 days at 2 mg a day; straight division, not a schedule |
| Female | No female-specific amount appears in any source, and this card does not supply one |
| Route | Subcutaneous injection; human oral uptake is estimated below 5 percent, which removes the oral option from the discussion |
Suggested Protocols
Three groupings show where the vial usually lands next to the rest of the line. Every pill opens the matching product page, and no combination here has been studied as a combination.
What to Expect
- First days. The sources describe nothing beyond a local reaction where the needle goes in; no early subjective effect is documented in people.
- Weeks 1-2. Users discuss how training loads feel, but that conversation has no clinical data behind it and is treated here as commentary.
- Weeks 2-4. The observation window vendor guides suggest; the mouse work that first drew attention to the compound ran over the same rough span.
- Laboratory background. The 2008 endurance and fibre-type findings came from mice, and the compound is studied as a metabolic signal rather than as a fuel or a fat burner.
- Combination reading. The report of around 40 percent of training genes being activated with GW501516 was a mouse experiment on untrained animals, not a promise of human performance.
- Limitation. There is no human endurance result for this material at all, and the cardiac programme that could have produced human data was stopped for lack of effect in 2010.
- Limitation. The compound has been prohibited since 2009, so a positive sample at a tested event is a rules matter with no room for interpretation.
Side Effects and Management
Almost nothing in this list comes from human use of the research material. Most entries are either animal observations, clinical-program signals or simple handling mistakes.
Reconstitution, Storage and Follow-Up
Handling is the one part of this file with firm numbers, so it is kept separate from the speculation.
